Im­mu­ni­ty­Bio inks roy­al­ty deal, pri­vate place­ment to raise $210M for blad­der can­cer drug com­bo

Im­mu­ni­ty­Bio has struck a roy­al­ty deal and a pri­vate place­ment to raise up to $320 mil­lion as it eyes a po­ten­tial ap­proval of its drug com­bo for blad­der can­cer, $210 mil­lion of which it’s al­ready re­ceived, the biotech an­nounced Tues­day.

The com­pa­ny and Ober­land Cap­i­tal agreed to a Rev­enue In­ter­est Pur­chase Agree­ment, with $200 mil­lion up­front — and an­oth­er $100 mil­lion if the FDA ap­proves the bi­o­log­ics li­cense ap­pli­ca­tion for its drug Ank­ti­va in com­bi­na­tion with Bacil­lus Cal­mette-Guérin to treat pa­tients with a sub­type of BCG-un­re­spon­sive non-mus­cle in­va­sive blad­der can­cer (NMIBC). In ex­change for the in­vest­ment, Ober­land gets tiered sin­gle-dig­it roy­al­ty pay­ments on net sales of Im­mu­ni­ty­Bio’s prod­ucts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER